CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug12 0.9%sodium chloride Wiki 1.00

Correlated MeSH Terms (0)


Name (Synonyms) Correlation

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.

NCT04445285 Covid19 Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) Drug: 0.9%sodium chloride
MeSH:Respiratory Insufficiency

Primary Outcomes

Description: All Cause Mortality at 28 days

Measure: Mortality at 28 days

Time: 28 days after enrollment

Description: To assess the effect of Pulmozyme® on the severity of respiratory failure, systemic inflammatory response, and multi-organ failure.

Measure: Systemic Therapeutic Response

Time: 5 days after enrollment

Secondary Outcomes

Description: Proportion of patients alive and free of invasive mechanical ventilation at 28 days invasive mechanical ventilation at 28 days

Measure: Respiratory Response

Time: 28 days

Description: Proportion of patients alive and discharged from the ICU at 28 days discharged from the ICU at 28 days

Measure: Legnth of ICU Stay

Time: 28 days

Description: Proportion of patients alive and discharged from the hospital at 28 days

Measure: Legnth of Hospital Stay

Time: 28 days

Description: Alive, respiratory failure-free days at 28 days

Measure: Respiratory Response

Time: 28 days

Description: Pulmonary Function Ratio at 5 days

Measure: Pulmonary Function

Time: 5 days


No related HPO nodes (Using clinical trials)